At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed diagnosis of Peripheral T-cell lymphoma (PTCL-NOS, AITL, ALCL ALK+, ALCL ALK-, or other investigator-approved PTCL subtypes)
- ✓At least one evaluable or measurable lesion per Lugano 2014 criteria (lymph node >1.5 cm, non-lymph node >1.0 cm)
- ✓Expected survival ≥3 months
- ✓Age 18-70 years (65-70 year-olds require comprehensive evaluation of physical fitness and tolerance)
- ✕Prior antitumor therapy including chemotherapy, targeted therapy, immunotherapy, or radiotherapy for lymphoma (except local radiotherapy for symptom relief)
- ✕Hypersensitivity to study drug or components
- ✕Uncontrolled systemic diseases (active infection, uncontrolled hypertension, diabetes)
- ✕Active hepatitis B (HBsAg+ and HBV DNA >1×10³ copy/mL) or hepatitis C (HCV RNA >1×10³ copy/mL)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06433362Phase 2RecruitingUpdate OverdueUpdated 25mo ago · Completion was 12mo agoA Single Arm, Open Label, Multi-center Study of Mitoxantrone Hydrochloride Liposome With Cyclophosphamide, Vincristine, Etoposide and Prednisone (CMOEP) in Treatment-Naive Patients With Peripheral T-Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating CMOEP for Peripheral T Cell Lymphoma. Currently recruiting, targeting 115 participants across 1 site.
Signals
Detailed Summary
This is a prospective, single arm, multicenter study to evaluate the safety and efficacy of CMOEP in patients with untreated peripheral T-cell lymphoma.
Study Details
Timeline
Interventions
Drug: Mitoxantrone hydrochloride liposome Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1, every 3 weeks; Drug: Cyclophosphamide Cyclophosphamide(750 mg/m\^2) on day 1,every 3 weeks; Drug: Vincristine Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1(Or at the discretion of the investigator, use other vinblastine drugs with the same mechanism, such as vindesine 3 mg/m2, the maximum dose of 4mg),every 3 weeks; Drug: Etoposide Etoposide (60 mg/ m2) will be administered by an intravenous infusion on day 1-3,every 3 weeks;